ClinicalTrials.gg
Sign In

BiosimilarDrug

IBI305 clinical trials

Also written IBI305.

A product of Bevacizumab; its studies count on that page too.

studies test it
5
open now
0
in phase 3
2
first study started
2019

How studies write it

Studies that test it under each name

Development codes

IBI305
4

Studies by the year they started

5 studies that test it; most in 2019 (2)

Studies that test IBI305, by start year
YearStudies
20192
20211
20222

By phase

A phase 1/2 study counts in both.

Phase 2
4
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular
2
Carcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Cholangiocarcinoma
1

Who runs them

Industry 2 · Other 3

Innovent Biologics (Suzhou) Co. Ltd. (2) · Sun Yat-sen University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Tianjin Medical University Cancer Institute and Hospital (1)

Often tested with

Tested in the same studies.

Sintilimab (3)

Studies

Open first, then newest update. How each study uses IBI305 is read from its arms, and is right about nine times in ten.

Testing it · 5

Given in every arm · 4 — IBI305 is usual care beside what is tested
As the comparator · 1 — what is tested is compared with IBI305